Latest Headlines

  1. Rancho BioSciences Launches OmicsHQ™: A Comprehensive, Curated, Multi-Omics Data Platform Built To Accelerate Drug Discovery 5/19/2026

    Today Rancho BioSciences, the premier tech-enabled data science partner for biopharma, announced the launch of OmicsHQTM, a unified catalog of expertly curated, standardized multi-omics datasets designed for immediate use in research, drug discovery, and AI/ML model development. The company is launching the product at BioIT World Conference & Expo, May 19, 2026, Boston, MA.

  2. Genedata Introduces AI-Native CMC Platform To Accelerate Drug Development And Manufacturing 5/19/2026

    Genedata, a Danaher company, and the leading provider of enterprise software solutions for biopharma R&D, today announced the launch of Genedata Vico™, an AI–native solution to accelerate CMC processes by enabling data-driven experimentation, process monitoring, and predictive risk assessment — helping organizations strengthen regulatory readiness and reduce development delays.

  3. QIAGEN To Advance AI-Driven Drug Discovery With Graph-Based AI And Curated Bioinformatics Knowledge With NVIDIA 5/19/2026

    QIAGEN announced at the 2026 BIO-IT World Conference & Expo in Boston that the QIAGEN Digital Insights bioinformatics business and its curated knowledge bases and bioinformatics expertise will be integrating NVIDIA accelerated computing and the NVIDIA BioNeMo platform to help researchers use AI more effectively in drug discovery.

  4. U.S. FDA Accepts Viatris New Drug Application For Fast-Acting Meloxicam For The Treatment Of Moderate-To-Severe Acute Pain 5/18/2026

    Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for MR-107A-02 (fast-acting meloxicam), a non-opioid, for the treatment of moderate-to-severe acute pain.

  5. Piramal Pharma Solutions Announces Partnership With Botanix To Support Drug Substance Development 5/18/2026

    Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), has entered a manufacturing and supply arrangement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited (ABN 70 009 109 755) (ASX:BOT) ("Botanix"), a commercial dermatology company.

  6. Creatv Bio Opens CLIA-Certified Laboratory To Support Oncology Drug Development 5/13/2026

    Creatv Bio, a Division of Creatv MicroTech, Inc. ("Creatv"), a liquid biopsy-based cancer diagnostic testing company, recently opened its full service CLIA-certified laboratory in Monmouth Junction, NJ.

  7. Nexentis Technologies Announces Optimization Of Hit Molecule At MitoCareX Bio Representing Key Drug Discovery Milestone 5/13/2026

    Nexentis Technologies Inc. ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd.

  8. AndzonBio2, The ALBORADA Drug Discovery Institute At The University Of Cambridge And Cambridge Enterprise Announce A Collaboration To Develop First-In-Class Therapeutics For Neuroinflammation 5/13/2026

    AndzonBio2 today announced the signature of agreements with the ALBORADA Drug Discovery Institute (ADDI) at the University of Cambridge and Cambridge Enterprise to advance a new class of therapeutics targeting neuroinflammation, a central driver of multiple neurodegenerative and neurological conditions such as Parkinson's, Alzheimer's, Amyotropic Lateral Sclerosis and other CNS disorders.

  9. Inside Information: Nanoform Signs First Exclusivity Agreement For Ultra-High Concentration Subcutaneous Delivery 5/12/2026

    Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), the medicine performance‑enhancing company, today announced that it has signed an exclusivity agreement with a U.S. biopharmaceutical company (Nasdaq listed, Mcap USD 1Bn+) for the application of Nanoform’s proprietary biologics nanoparticle technology to support the development of differentiated subcutaneous biologic medicines.

  10. Government's Sovereign AI Invests In British-Founded AI Company Redefining How Medicines Are Designed 5/12/2026

    Isomorphic Labs, a London-founded and headquartered company, using AI to design and develop new medicines, has been named as the latest firm to receive investment from the UK Government’s Sovereign AI Fund today (Tuesday 12 May).